CD73 Is an Immunometabolic Biomarker of Poor Prognosis in Patients With Primary cSCC and Hematologic Malignancy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
CD73 Is an Immunometabolic Biomarker of Poor Prognosis in Patients With Primary Cutaneous Squamous Cell Carcinoma and Hematologic Malignancy
Dermatol Surg 2024 Jul 08;[EPub Ahead of Print], V Saeidi, SR Jackson Cullison, NA Doudican, JA Carucci, ML StevensonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.